Genzyme leads drug stocks higher

Genzyme Corp. was the lead advancer among the large-cap drug stocks in early trading, with shares rising almost 4% to $70.16.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.